Scientists expose COPD patients to ozone to uncover Pollution's hidden impact
NCT ID NCT04669743
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at how ozone, a common air pollutant, affects immune cells in the lungs of people with COPD. Researchers will expose 72 participants (including healthy non-smokers, smokers without COPD, and COPD patients) to ozone in a controlled chamber and track changes in their lung immune cells. The goal is to understand why pollution triggers COPD flare-ups, which could lead to better prevention strategies.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- ozone exposure
- What this could lead to
- If successful, this could help explain why air pollution worsens COPD symptoms, pointing toward new ways to prevent flare-ups.
- What could go wrong
- This is an early observational study with no treatment being tested. Results may not lead to direct patient benefits or apply to real-world pollution scenarios.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 72 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2016
- Expected to finish
-
Dec 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
45 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Group 1: 1. No diagnosis of COPD or asthma. 2. No spirometric evidence of airflow obstruction as determined by FEV1/FVC ratio = or \>0.7. 3. Less than 1 pack year history of tobacco smoking and no tobacco use within the past 12 months. Group 2: 1. No diagnosis of COPD or asthma. 2. No spirometric evidence of airflow obstruction as determined by FEV1/FVC ratio = or \>0.7. 3. Current smoker with history of at least 20 pack-years smoking. Group 3: 1. Diagnosis of COPD as determined by GOLD criteria (FEV1/FVC ratio \<0.7). 2. COPD severity of GOLD stage II or III (FEV1 \>40% predicted). 3. Smoking Status: Former smokers with history of at least 20 pack-years smoking. Group 4: 1. Diagnosis of COPD as determined by GOLD criteria (FEV1/FVC ratio \<0.7). 2. COPD severity of GOLD stage II or III (FEV1 \>40% predicted). 3. Smoking Status: Current smokers with history of at least 20 pack-years smoking. During subject screening visit, Albuterol is used to determine whether the subjects have COPD based on the Global Initiative on Obstructive Lung Diseases (GOLD) criteria. Regardless of whether the subject has reversibility to Albuterol or not, if they have an abnormal ratio after inhalation of Albuterol, they would meet the GOLD criteria for COPD and will be included in the study. Exclusion Criteria: 1. History of IV drug use or inhalation of recreational drugs other than marijuana: A- within the past 20 years. B- more than 100 usage. C- longer than 1 year. 2. COPD severity of GOLD stage IV. 3. Inability to walk briskly or run on treadmill or pedal on ergometer to perform the study-required moderate exercise level (achieve minute ventilation of 15 to 20 L/min/m2 body surface area). 4. Pregnant/breast feeding. 5. Serious and active heart conditions - defined by stable or unstable angina, recent myocardial infarction (within the last 2 years), active congestive heart failure, ischemic cardiomyopathy. 6. Malnourishment - determined by BMI less than 19. If subject has BMI greater or equal to 19, but has a history of malnourishment, study staff will measure albumin level of subject's blood after initial blood draw. Albumin level must be greater than 2.5 mg per deciliter, or subject will be excluded. 7. Liver cirrhosis. 8. History of chronic active Hepatitis B or C 9. On visits where moderate sedation is preformed, subject are required to have an escort home. Inability to secure a ride home will result in the subject being ineligible for the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Airway disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
San Francisco VA Medical Center
San Francisco, California, 94121, United States
-
University of California, San Francisco
San Francisco, California, 94122, United States
-
Zuckerberg San Francisco General Hospital and Trauma Center
San Francisco, California, 94110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can virtual reality help COPD patients breathe easier in hospital?
- Can a COPD flare stun the heart? study watches for hidden strain
- Can better training get doctors to talk about what matters most to dying veterans?
- Can an injected antibody calm inflamed lungs and cut COPD flare-ups?
- Can a machine breathe better than a nurse? automated oxygen system tested in COPD
- Detailed lung scans could map COPD damage more precisely